Beauty & Cosmetics Growth
30%
+30% YoY
Fourth consecutive quarter of over 20% growth in the segment.
EPL
Other
14 May 2026
EPL Ltd — Q4 FY26
EPL delivered a strong Q4 FY26 with revenue growth of 17.6% YoY, the highest in five years, driven by a 30% surge in beauty & cosmetics and a recovery in oral care (up 10%).
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
EPL delivered a strong Q4 FY26 with revenue growth of 17.6% YoY, the highest in five years, driven by a 30% surge in beauty & cosmetics and a recovery in oral care (up 10%). EBITDA grew 17.2% with margins sustained above 20% for the seventh consecutive quarter. All four regions posted double-digit growth, led by EAP (25%) and Americas (24.1%). The proposed merger with Indova was announced, expected to create a nearly $1B platform. Management guided for continued low double-digit revenue growth (11-13%) and reiterated confidence in passing through raw material cost inflation from the Middle East crisis. Key risk: volatility in raw material availability and cost could pressure near-term margins if pass-through lags.
ईपीएल ने वित्त वर्ष 2026 की चौथी तिमाही में शानदार प्रदर्शन किया। कंपनी की कमाई पिछले साल की तुलना में 17.6% बढ़ी, जो पांच साल में सबसे ज्यादा है। इसकी मुख्य वजह ब्यूटी और कॉस्मेटिक्स में 30% की उछाल और ओरल केयर में 10% की रिकवरी रही। कंपनी का मुनाफा (EBITDA) 17.2% बढ़ा और लगातार सातवीं तिमाही 20% से ऊपर रहा। सभी चारों क्षेत्रों में दोहरे अंकों में वृद्धि हुई, खासकर एशिया-प्रशांत में 25% और अमेरिका में 24.1%। इंडोवा के साथ विलय की घोषणा हुई, जिससे लगभग 1 अरब डॉलर का प्लेटफॉर्म बनेगा। प्रबंधन ने अगली तिमाही में 11-13% कमाई बढ़ोतरी का अनुमान जताया है। हालांकि, कच्चे माल की कीमतों में उतार-चढ़ाव से मुनाफे पर दबाव पड़ सकता है।
Key Numbers
Net Debt to EBITDA
0.52x
Improved from prior period
Further deleveraging of balance sheet; strong cash flow generation.
ROCE
19%
+96bps YoY
Return on capital employed expanded by 96 basis points.
Sustainable Tube Sales Mix
38%
Steady progress
Sustainable tube formats contributed 38% of total sales.
What Changed vs Last Quarter
NEW
Revenue growth guidance of 11-13%
Long-term low double-digit revenue growth guidance maintained; FY26 full-year growth was 13%.
NEW
EBITDA growth to be slightly ahead of revenue
Management expects EBITDA growth to outpace revenue growth over the long term.
NEW
Merger completion expected by Q4 FY27
Proposed merger with Indova expected to complete in about 12 months from announcement (end of March 2026).
NEW
Capex to remain elevated for B&C growth
Investments in beauty & cosmetics capacity and innovation will keep capex above depreciation in FY27.
DROPPED
Sustained double-digit revenue growth
Management reiterated long-term guidance of sustained double-digit revenue growth, with EBITDA growth slightly ahead.
DROPPED
Europe margins to return to mid-teens
Management expects Europe margins to improve to mid-teen levels in coming quarters through operational initiatives.
DROPPED
Beauty & cosmetics to grow in high teens
Beauty & cosmetics segment expected to continue growing in high teens, with significant headroom for market share gains.
DROPPED
Gradual ROCE improvement
ROCE expected to improve year-on-year through multiple levers, though no specific year-level guidance provided.
NEW RISK
Middle East crisis impacting raw material availability and cost
The crisis has affected both availability and cost of key raw materials; management is proactively managing but uncertainty remains.
NEW RISK
Potential lag in non-contractual price pass-through
Analyst questioned whether non-contractual customers may have a lag in accepting price increases; management claimed no lag but this is unproven.
NEW RISK
Margin dilution from elevated capex and investments
High capex (₹480 cr in FY26) and investments in B&C may pressure near-term margins despite revenue growth.
NEW RISK
Merger execution and regulatory approval delays
The merger with Indova requires multiple approvals; timeline may extend beyond Q4 FY27, delaying synergies.
RISK GONE
Europe margin recovery may be delayed
Europe margins were impacted by short-term operational issues and adverse mix; recovery to mid-teens may take longer than expected.
RISK GONE
Commodity price volatility could pressure margins
If polymer prices rise sharply, despite pass-through mechanisms, there is risk of margin compression if negotiations lag.
RISK GONE
Thailand ramp-up may be gradual
Thailand plant only commercialized in November; scale-up is organic without an anchor customer, so revenue contribution may be slow.
RISK GONE
Customer concentration in oral care
Oral care segment is dominated by a few large customers; any slowdown or inventory correction could impact growth.
Management Guidance
Revenue growth guidance of 11-13%
Long-term low double-digit revenue growth guidance maintained; FY26 full-year growth was 13%.
Management guidance revenueEBITDA growth to be slightly ahead of revenue
Management expects EBITDA growth to outpace revenue growth over the long term.
Management guidance marginsMerger completion expected by Q4 FY27
Proposed merger with Indova expected to complete in about 12 months from announcement (end of March 2026).
Management guidance otherCapex to remain elevated for B&C growth
Investments in beauty & cosmetics capacity and innovation will keep capex above depreciation in FY27.
Management guidance capexKey Risks
Middle East crisis impacting raw material availability and cost
The crisis has affected both availability and cost of key raw materials; management is proactively managing but uncertainty remains.
high · management_commentaryPotential lag in non-contractual price pass-through
Analyst questioned whether non-contractual customers may have a lag in accepting price increases; management claimed no lag but this is unproven.
medium · analyst_questionMargin dilution from elevated capex and investments
High capex (₹480 cr in FY26) and investments in B&C may pressure near-term margins despite revenue growth.
medium · data_observationMerger execution and regulatory approval delays
The merger with Indova requires multiple approvals; timeline may extend beyond Q4 FY27, delaying synergies.
medium · management_commentaryNotable Quotes
This is the highest ever revenue growth in the last 5 years. This is also the fourth consecutive quarter of double-digit revenue growth reflecting the consistency and strength of our performance.
Our strategic shift towards beauty and cosmetics is now translating into results with the segment delivering fourth consecutive quarter of over 20% growth.
We are confident that we will recover the full cost impact and we do not think that there will be a lag in recovery of the cost.
Frequently Asked Questions
What was EPL's revenue in Q4 FY26?
EPL reported revenue of ₹1,300 Cr in Q4 FY26, representing a +17.6% change compared to the same quarter last year.
What guidance did EPL management give for FY27?
Revenue growth guidance of 11-13%: Long-term low double-digit revenue growth guidance maintained; FY26 full-year growth was 13%. EBITDA growth to be slightly ahead of revenue: Management expects EBITDA growth to outpace revenue growth over the long term. Merger completion expected by Q4 FY27: Proposed merger with Indova expected to complete in about 12 months from announcement (end of March 2026). Capex to remain elevated for B&C growth: Investments in beauty & cosmetics capacity and innovation will keep capex above depreciation in FY27.
What are the key risks for EPL in FY27?
Key risks include Middle East crisis impacting raw material availability and cost — The crisis has affected both availability and cost of key raw materials; management is proactively managing but uncertainty remains.; Potential lag in non-contractual price pass-through — Analyst questioned whether non-contractual customers may have a lag in accepting price increases; management claimed no lag but this is unproven.; Margin dilution from elevated capex and investments — High capex (₹480 cr in FY26) and investments in B&C may pressure near-term margins despite revenue growth.; Merger execution and regulatory approval delays — The merger with Indova requires multiple approvals; timeline may extend beyond Q4 FY27, delaying synergies..
Did EPL meet its previous quarter's guidance?
Of 3 tracked promises, management 0 met, 0 close, 3 missed.
Where can I read the full EPL Q4 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.